tbuckley/cabot-search huggingface dataset:
Association of Changes in Air Quality With Incident Asthma in Children in California, 1993-2014
Authors: Erika Garcia, Kiros T. Berhane, Talat Islam, Rob McConnell, Robert Urman, Zhanghua Chen, Frank D. Gilliland
Journal: JAMA (2019)

<h3>Importance</h3> Exposure to air pollutants is a well-established cause of asthma exacerbation in children; whether air pollutants play a role in the development of childhood asthma, however, remains uncertain. <h3>Objective</h3> To examine whether decreasing regional air pollutants were associated with reduced incidence of childhood asthma. <h3>Design, Setting, and Participants</h3> A multilevel longitudinal cohort drawn from 3 waves of the Southern California Children’s Health Study over a period of air pollution decline. Each cohort was followed up from 4th to 12th grade (8 years): 1993-2001, 1996-2004, and 2006-2014. Final follow-up for these data was June 2014. Population-based recruitment was from public elementary schools. A total of 4140 children with no history of asthma and residing in 1 of 9 Children’s Health Study communities at baseline were included. <h3>Exposures</h3> Annual mean community-level ozone, nitrogen dioxide, and particulate matter less than 10 μm (PM<sub>10</sub>) and less than 2.5 μm (PM<sub>2.5</sub>) in the baseline year for each of 3 cohorts. <h3>Main Outcomes and Measures</h3> Prospectively identified incident asthma, collected via questionnaires during follow-up. <h3>Results</h3> Among the 4140 children included in this study (mean [SD] age at baseline, 9.5 [0.6] years; 52.6% female [n = 2 179]; 58.6% white [n = 2273]; and 42.2% Hispanic [n = 1686]), 525 incident asthma cases were identified. For nitrogen dioxide, the incidence rate ratio (IRR) for asthma was 0.80 (95% CI, 0.71-0.90) for a median reduction of 4.3 parts per billion, with an absolute incidence rate decrease of 0.83 cases per 100 person-years. For PM<sub>2.5</sub>, the IRR was 0.81 (95% CI, 0.67-0.98) for a median reduction of 8.1 μg/m<sup>3</sup>, with an absolute incidence rate decrease of 1.53 cases per 100 person-years. For ozone, the IRR for asthma was 0.85 (95% CI, 0.71-1.02) for a median reduction of 8.9 parts per billion, with an absolute incidence rate decrease of 0.78 cases per 100 person-years. For PM<sub>10</sub>, the IRR was 0.93 (95% CI, 0.82-1.07) for a median reduction of 4.0 μg/m<sup>3</sup>, with an absolute incidence rate decrease of 0.46 cases per 100 person-years. <h3>Conclusions and Relevance</h3> Among children in Southern California, decreases in ambient nitrogen dioxide and PM<sub>2.5</sub>between 1993 and 2014 were significantly associated with lower asthma incidence. There were no statistically significant associations for ozone or PM<sub>10</sub>.
EFFECTIVENESS OF PROPHYLACTIC MUCOSAL CLOSURE AFTER DUODENAL ENDOSCOPIC SUBMUCOSAL DISSECTION TO PREVENT HAZARDOUS COMPLICATIONS
Authors: S Hoteya, Y Okamoto, Y Ochiai, Y Suzuki, M Tanaka, K Nomura, H Odagiiri, S Yamashita, D Kikchi, A Matsui, T Miani, T Iizuka, Y Tateiri, T Tsubaki, A Koyama, T Araki
Journal: Endoscopy (2019)

The endoscopic submucosal dissection (ESD) for superficial non-ampullary duodenal epithelial tumors (SNADETs) is technically challenging because of anatomical specificities and, to date, has not been validated concerning the high rate of complications. Especially, postoperative complications such as delayed perforation and bleeding are often hazardous. The aims of this study were to clarify the feasibility and effectiveness of prophylactic closure for large mucosal defect after duodenal ESD using endoscopic closing technique such as endoloop method or grasping method.
The role of macrophages in the resolution of inflammation
Authors: Satoshi Watanabe, Michael Alexander, Alexander V. Misharin, G.R. Scott Budinger
Journal: Journal of Clinical Investigation (2019)

Macrophages are tissue-resident or infiltrated immune cells critical for innate immunity, normal tissue development, homeostasis, and repair of damaged tissue. Macrophage function is a sum of their ontogeny, the local environment in which they reside, and the type of injuries or pathogen to which they are exposed. In this Review, we discuss the role of macrophages in the restoration of tissue function after injury, highlighting important questions about how they respond to and modify the local microenvironment to restore homeostasis.
Patient-reported symptoms during and after direct-acting antiviral therapies for chronic hepatitis C: The PROP UP study
Authors: Donna M. Evon, Souvik Sarkar, Jipcy Amador, Anna S. Lok, Richard K. Sterling, Paul W. Stewart, Bryce B. Reeve, Marina Serper, Nancy Reau, K. Rajender Reddy, Adrian M. Di Bisceglie, David R. Nelson, Carol E. Golin, Joseph K. Lim, Michael W. Fried
Journal: Journal of Hepatology (2019)
NBI GUIDED CRUSH CYTOLOGY COMPARED TO HISTOPATHOLOGY – EARLY DIAGNOSIS &amp; FASTER TREATMENT INITIATION
Authors: P Desai, M Kabrawala, R Mehta, S Nandwani, C Patel, P Kalra, R Prajapati, N Patel
Journal: Endoscopy (2019)

Crush cytology for gastrointestinal (GI) lesions is not studied much. We studied utility of crush cytology in diagnosis of GI lesions compared to conventional histopatholgy. 94 suspected cases of malignancy of esophagus, stomach, ampulla and colorectum, undergoing endoscopy from August 2018 to November 2018 were included in the study. For any tumor, an area was targeted for biopsy using NBI criteria, first 2 biopsies taken on a slide, crush smears made, stained with H&E and studied. then Correlation done with conventional histopathology from remaining bits. Diagnostic values, accuracy, sensitivity, specificity, and positive and negative predictive values calculated.
TSHOULD WE SYSTEMATICALLY PERFORM AN ESOPHAGOGASTRODUODENOSCOPY (EGD) IN ANY PATIENT WITH IBD?
Authors: R Benjira, H Elarabi, A Lamine Sejai, M Lahlali, N Lahmidani, M Elyousfi, DA Benajah, M Elabkari, A Ibrahimi, H Abid
Journal: Endoscopy (2019)

Certain complementary examinations are essential to make the diagnosis of inflammatory bowel disease (IBD), as well as to establish an initial mapping that seems to be a crucial element in the therapeutic choice. However, the systematic search for lesions in the upper digestive tract is still controversial. The aim of this work is to study the contribution EGD in IBD.
Total circulating cell-free DNA as a prognostic biomarker in metastatic colorectal cancer before first-line oxaliplatin-based chemotherapy
Authors: J. Hamfjord, T.K. Guren, O. Dajani, J.S. Johansen, B. Glimelius, H. Sorbye, P. Pfeiffer, O.C. Lingjærde, K.M. Tveit, E.H. Kure, N. Pallisgaard, K.-L.G. Spindler
Journal: Annals of Oncology (2019)
MULTIPLE OVER-THE-SCOPE CLIPS (OTSCS) AS FIRST-LINE THERAPY OF WIDE DUODENAL BLEEDING ULCER IN ANTICOAGULATED PATIENT: A VIDEO REPORT
Authors: T Gabbani, S Deiana, P Soriani, V Mirante, M Manno
Journal: Endoscopy (2019)

The Over-The-Scope Clip (OTSC, Ovesco Endoscopy GmbH, Tübingen, Germany) is a safe and effective tool for the treatment of bleeding and perforations of the gastrointestinal (GI) tract.
Cardiac Implantable Electronic Device Therapy in Heart Failure
Authors: Ayman A. Hussein, Bruce L. Wilkoff
Journal: Circulation Research (2019)

The population of patients with heart failure continues to grow, which introduced significant challenges in clinical practice related to the management of cardiac arrhythmia and advanced heart failure syndromes. Device therapy has increasingly become essential in the management of life-threatening arrhythmia and clinical heart failure in this population. This review will discuss the use of cardiac implantable electronic devices in heart failure with primary focus on sudden cardiac death prevention and cardiac resynchronization, including published evidence and evolving technologies.
<i>Diabetes Care</i> Editors’ Expert Forum 2018: Managing Big Data for Diabetes Research and Care
Authors: Matthew C. Riddle, Lawrence Blonde, Hertzel C. Gerstein, Edward W. Gregg, Rury R. Holman, John M. Lachin, Gregory A. Nichols, Alexander Turchin, William T. Cefalu
Journal: Diabetes Care (2019)

Technological progress in the past half century has greatly increased our ability to collect, store, and transmit vast quantities of information, giving rise to the term “big data.” This term refers to very large data sets that can be analyzed to identify patterns, trends, and associations. In medicine—including diabetes care and research—big data come from three main sources: electronic medical records (EMRs), surveys and registries, and randomized controlled trials (RCTs). These systems have evolved in different ways, each with strengths and limitations. EMRs continuously accumulate information about patients and make it readily accessible but are limited by missing data or data that are not quality assured. Because EMRs vary in structure and management, comparisons of data between health systems may be difficult. Registries and surveys provide data that are consistently collected and representative of broad populations but are limited in scope and may be updated only intermittently. RCT databases excel in the specificity, completeness, and accuracy of their data, but rarely include a fully representative sample of the general population. Also, they are costly to build and seldom maintained after a trial’s end. To consider these issues, and the challenges and opportunities they present, the editors of Diabetes Care convened a group of experts in management of diabetes-related data on 21 June 2018, in conjunction with the American Diabetes Association’s 78th Scientific Sessions in Orlando, FL. This article summarizes the discussion and conclusions of that forum, offering a vision of benefits that might be realized from prospectively designed and unified data-management systems to support the collective needs of clinical, surveillance, and research activities related to diabetes.
Stimulating Cardiogenesis as a Treatment for Heart Failure
Authors: Todd R. Heallen, Zachary A. Kadow, Jong H. Kim, Jun Wang, James F. Martin
Journal: Circulation Research (2019)

After myocardial injury, cardiomyocyte loss cannot be corrected by using currently available clinical treatments. In recent years, considerable effort has been made to develop cell-based cardiac repair therapies aimed at correcting for this loss. An exciting crop of recent studies reveals that inducing endogenous repair and proliferation of cardiomyocytes may be a viable option for regenerating injured myocardium. Here, we review current heart failure treatments, the state of cardiomyocyte renewal in mammals, and the molecular signals that stimulate cardiomyocyte proliferation. These signals include growth factors, intrinsic signaling pathways, microRNAs, and cell cycle regulators. Animal model cardiac regeneration studies reveal that modulation of exogenous and cell-intrinsic signaling pathways can induce reentry of adult cardiomyocytes into the cell cycle. Using direct myocardial injection, epicardial patch delivery, or systemic administration of growth molecules, these studies show that inducing endogenous cardiomyocytes to self-renew is an exciting and promising therapeutic strategy to treat cardiac injury in humans.
CECDAIIC – A NEW SCORE FOR PANENTERIC EVALUATION IN CROHN'S DISEASE PATIENTS
Authors: C Arieira, R Magalhães, F Dias de Castro, P Boal Carvalho, B Rosa, MJ Moreira, J Cotter
Journal: Endoscopy (2019)

Crohn's Disease (CD) is a chronic and progressive disease. Panenteric capsule endoscopy has been used to assess both the small and large bowel in a single examination. The Capsule Endoscopy Crohn's Disease Activity Index (CECDAI) was initially devised to measure mucosal disease activity in small bowel, although in 2018 it was extended to the colon for standardization of inflammatory activity (CECDAIic).
Intérêt de la dévolvulation endoscopique dans le traitement du volvulus du colon sigmoïde
Authors: M Sabbah, H Jlassi, N Bibani, D Trad, H Elloumi, A Ouakaa Kchaou, D Gargouri
Journal: Endoscopy (2019)

Le volvulus du colon sigmoïde (VCS) est la torsion de l'anse sigmoïde sur son axe mésocolique entraînant ainsi une occlusion intestinale aiguë basse par strangulation. La prise en charge thérapeutique du VCS en urgence est controversée entre le traitement endoscopique et chirurgical.
EUS-GUIDED DUODENO-JEJUNOSTOMY (EUS-DJ): A NOVEL ENDOSCOPIC ANASTOMOSIS FOR PALLIATION OF GASTRIC OUTLET OBSTRUCTION (GOO)
Authors: S Bazaga, R Sánchez-Ocaña, A Yaiza Carbajo, FJ García-Alonso, M de Benito, C de la Serna Higuera, M Pérez-Miranda
Journal: Endoscopy (2019)

We describe EUS-DJ as a novel salvage endoscopic approach in a patient with native GI anatomy in whom attempts at both duodenal SEMS placement and EUS-guided gastroenterostomy were unsuccessful.
Reply to: “Role of HGF for reprogramming human liver progenitor cells: Non-essential but stimulative supplement”
Authors: Seung Bum Lee, Yohan Kim, Kyojin Kang, Valentina M. Factor, Daekwan Seo, Ji-Hye Yim, Dongho Choi, Jaemin Jeong
Journal: Journal of Hepatology (2019)
The Dangers of Ignoring the Beers Criteria—The Prescribing Cascade
Authors: Kim H. DeRhodes
Journal: JAMA Internal Medicine (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
APPLICATION IN OUR CENTER OF THE CLINICAL GUIDE FOR ENDOSCOPIC RESECTION OF COLON POLYPS IN THE MANAGEMENT OF ADENOCARCINOMA PT1
Authors: A Glez-Cotorruelo Glez, A Álvarez Delgado, AM Soler, AB Prieto Bermejo, A Jiménez Jurado, M Garcia Prada, ÁF Marcos Martin, P Rodríguez López, S Del Carmen Martínez, A Rodríguez Pérez
Journal: Endoscopy (2019)

The pT1 adenocarcinoma resected endoscopically poses a challenge in terms of its management. In some cases, there is a lack of scientific evidence that supports the need of additional invasive treatments. The Spanish Society of digestive Endoscopy suggests the classification of these injuries according to the risk of dissemination, multidisciplinary advice and individualized decision for patients at intermediate/high risk.
Cognitive Dysfunction in Systemic Lupus Erythematosus: A Case for Initiating Trials
Authors: Nina Kello, Erik Anderson, Betty Diamond
Journal: Arthritis & Rheumatology (2019)

Cognitive dysfunction (CD) is an insidious and underdiagnosed manifestation of systemic lupus erythematosus (SLE) that has a considerable impact on quality of life, which can be devastating. Given the inconsistencies in the modes of assessment and the difficulties in attribution to SLE, the reported prevalence of CD ranges from 5% to 80%. Although clinical studies of SLE‐related CD have been hampered by heterogeneous subject populations and a lack of sensitive and standardized cognitive tests or other validated objective biomarkers for CD, there are, nonetheless, strong data from mouse models and from the clinical arena that show CD is related to known disease mechanisms. Several cytokines, inflammatory molecules, and antibodies have been associated with CD. Proposed mechanisms for antibody‐ and cytokine‐mediated neuronal injury include the abrogation of blood–brain barrier integrity with direct access of soluble molecules in the circulation to the brain and ensuing neurotoxicity and microglial activation. No treatments for SLE‐mediated CD exist, but potential candidates include agents that inhibit microglial activation, such as angiotensin‐converting enzyme inhibitors, or that protect blood–brain barrier integrity, such as C5a receptor blockers. Structural and functional neuroimaging data have shown a range of regional abnormalities in metabolism and white matter microstructural integrity in SLE patients that correlate with CD and could in the future become diagnostic tools and outcome measures in clinical trials aimed at preserving cognitive function in SLE.
10-Year Risk Equations for Incident Heart Failure in the General Population
Authors: Sadiya S. Khan, Hongyan Ning, Sanjiv J. Shah, Clyde W. Yancy, Mercedes Carnethon, Jarett D. Berry, Robert J. Mentz, Emily O’Brien, Adolfo Correa, Navin Suthahar, Rudolf A. de Boer, John T. Wilkins, Donald M. Lloyd-Jones
Journal: Journal of the American College of Cardiology (2019)
Is Echocardiography Critical in Patients With Kawasaki Disease With a <i>z</i> Score Less Than 2 to 6 Weeks From Onset?
Authors: Ilaria Maccora, Giovanni Battista Calabri, Gabriele Simonini
Journal: JAMA Pediatrics (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
Nonblanchable erythema for predicting pressure ulcer development: a systematic review with an individual participant data meta‐analysis
Authors: C. Shi, L.J. Bonnett, J.C. Dumville, N. Cullum
Journal: British Journal of Dermatology (2019)

BackgroundEmpirical evidence is uncertain regarding the value of nonblanchable erythema in predicting the incidence of stage 2 (or more severe) pressure ulcers.
Pathological complete response in early breast cancer patients undergoing neoadjuvant chemotherapy: Focus on Ki-67 and molecular subtypes
Authors: B.L. Rapoport, J. Barnard-Tidy, R.I. Van Eeden, T. Smit, S. Nayler, C. Benn
Journal: Annals of Oncology (2019)

Background: Pathologic complete response (pCR) following neoadjuvant chemotherapy (NAC) has been proposed as a surrogate endpoint for of long-term clinical benefit, such as disease-free survival, event-free survival, and overall survival in patients (pts) with early breast cancer (BC). The association between molecular subtypes, clinicopathological features, and pCR rate in early BC pts treated with NAC were examined. Methods: We retrospectively analyzed data of 208 pts undergoing NAC. Luminal A was documented in 12 pts, Luminal B in 42 pts, Her-2+ in 38 pts (Her-2+ ER-/PR- = 12; Her-2+ ER+ and/ or PR+ = 26) and triple negative breast cancers (TNBC) in 116 pts. Pathological complete response was defined as the complete disappearance of the invasive cancer in the breast and absence of tumor in the axillary lymph nodes. Results: The pCR rate of the entire cohort was 45%. At 4 years 95% of pts who attained a pCR were disease free compared to 78% of pts who did not (log rank test Chi2 =10.775, p < 0.01). Among TNBC subtype, at 4 years 95% of pts who attained a pCR were disease free compared to 77% of pts who did not (log rank test Chi2 =7.525, p < 0.01). On univariate analysis factors associated with higher pCR included molecular subtype (TNBC 58%, Her-2+ ER-/PR- =75%, Her-2+ ER+ and/or PR+ = 46% and Luminal A + B was 11%, Chi2 =37.03, p < 0.00000), primary tumor size (T1=62% vs. T2=46% vs. T3=16% vs. T4=18%, Chi2=15.16, p < 0.00168), nodal disease (N0=53% vs. N1=39%, Chi2=3.76, p < 0.05), age (< than 50 years = 55% vs ≥ 50 years = 39%, Chi2 = 5.05, p < 0.02) ER receptor status (neg=60% vs. pos=21%, Chi2=30.08 p < 0.00000), PR receptor status (neg=58% vs. pos=16%, Chi2=30.1 p < 0.00000), Ki67 (>40=59% vs.14-39=36% vs. <14=6%,Chi2=22.09 p < 0.00060) and stage (I = 80% vs. IIA=49% vs. IIB=40% vs. III=22%, Chi2=22.09 p < 0.0004). Menopausal status, ethnicity, extra-nodal spread and lympho-vascular invasion were not associated with a higher pCR rate. In a logistic regression model Ki-67 as a continuous variable (p < 0.02) and TNBC subtype (p < 0.04) retained its significance; while tumor size, stage of disease, nodal status, ER and PR lost significance. Conclusions: TNBC molecular subtype and high Ki67 are associated with a higher pCR rate in early BC pts undergoing NAC. Legal entity responsible for the study: The Medical Oncology Centre of Rosebank. Funding: Has not received any funding. Disclosure: All authors have declared no conflicts of interest.
TAS-120 Overcomes Resistance to ATP-Competitive FGFR Inhibitors in Patients with FGFR2 Fusion–Positive Intrahepatic Cholangiocarcinoma
Authors: Lipika Goyal, Lei Shi, Leah Y. Liu, Ferran Fece de la Cruz, Jochen K. Lennerz, Srivatsan Raghavan, Ignaty Leschiner, Liudmila Elagina, Giulia Siravegna, Raymond W.S. Ng, Phuong Vu, Krushna C. Patra, Supriya K. Saha, Raul N. Uppot, Ron Arellano, Stephanie Reyes, Takeshi Sagara, Sachie Otsuki, Brandon Nadres, Heather A. Shahzade, Ipsita Dey-Guha, Isobel J. Fetter, Islam Baiev, Emily E. Van Seventer, Janet E. Murphy, Cristina R. Ferrone, Kenneth K. Tanabe, Vikram Deshpande, James J. Harding, Rona Yaeger, Robin K. Kelley, Alberto Bardelli, A. John Iafrate, William C. Hahn, Cyril H. Benes, David T. Ting, Hiroshi Hirai, Gad Getz, Dejan Juric, Andrew X. Zhu, Ryan B. Corcoran, Nabeel Bardeesy
Journal: Cancer Discovery (2019)

Abstract ATP-competitive fibroblast growth factor receptor (FGFR) kinase inhibitors, including BGJ398 and Debio 1347, show antitumor activity in patients with intrahepatic cholangiocarcinoma (ICC) harboring activating FGFR2 gene fusions. Unfortunately, acquired resistance develops and is often associated with the emergence of secondary FGFR2 kinase domain mutations. Here, we report that the irreversible pan-FGFR inhibitor TAS-120 demonstrated efficacy in 4 patients with FGFR2 fusion–positive ICC who developed resistance to BGJ398 or Debio 1347. Examination of serial biopsies, circulating tumor DNA (ctDNA), and patient-derived ICC cells revealed that TAS-120 was active against multiple FGFR2 mutations conferring resistance to BGJ398 or Debio 1347. Functional assessment and modeling the clonal outgrowth of individual resistance mutations from polyclonal cell pools mirrored the resistance profiles observed clinically for each inhibitor. Our findings suggest that strategic sequencing of FGFR inhibitors, guided by serial biopsy and ctDNA analysis, may prolong the duration of benefit from FGFR inhibition in patients with FGFR2 fusion–positive ICC. Significance: ATP-competitive FGFR inhibitors (BGJ398, Debio 1347) show efficacy in FGFR2-altered ICC; however, acquired FGFR2 kinase domain mutations cause drug resistance and tumor progression. We demonstrate that the irreversible FGFR inhibitor TAS-120 provides clinical benefit in patients with resistance to BGJ398 or Debio 1347 and overcomes several FGFR2 mutations in ICC models. This article is highlighted in the In This Issue feature, p. 983